Albumin as a delivery carrier for rheumatoid arthritis

Journal of Nanomedicine and Nanotechnology

Volumn 4, Issue 4, 2013, Pages

  Ren, Ke ^a   Dusad, Anand ^a   Dong, Rui ^b   Quan, Lingdong ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c Hospital for Special Surgery   (United States)

Author keywords

Albumin; Delivery carrier; Inflammation; Rheumatoid arthritis

Indexed keywords

EID: 84884783869     PISSN: None     EISSN: 21577439     Source Type: Journal    
DOI: 10.4172/2157-7439.1000176     Document Type: Review

References (35)

1. Kratz F, Elsadek B (2012) Clinical impact of serum proteins on drug delivery. J Control Release 161: 429-445.
2. Elsadek B, Kratz F (2012) Impact of albumin on drug delivery--new applications on the horizon. J Control Release 157: 4-28.
3. Neumann E, Frei E, Funk D, Becker MD, Schrenk HH, et al. (2010) Native albumin for targeted drug delivery. Expert Opin Drug Deliv 7: 915-925.
4. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132: 171-183.
5. van de Stadt RJ, van de Voorde-Vissers E, Feltkamp-Vroom TM (1980) Metabolic and secretory properties of peripheral and synovial granulocytes in rheumatoid arthritis. Arthritis Rheum 23: 17-23.
6. Henderson B, Bitensky L, Johnstone JJ, Catterall A, Chayen J (1979) Metabolic alterations in human synovial lining cells in pigmented villonodular synovitis. Ann Rheum Dis 38: 463-466.
7. Wilkinson P, Jeremy R, Brooks FP, Hollander JL (1965) The mechanism of hypoalbuminemia in rheumatoid arthritis. Ann Intern Med 63: 109-114.
8. Ballantyne FC, Fleck A, Dick WC (1971) Albumin metabolism in rheumatoid arthritis. Ann Rheum Dis 30: 265-270.
9. Levick JR (1981) Permeability of rheumatoid and normal human synovium to specific plasma proteins. Arthritis Rheum 24: 1550-1560.
10. Henson PM (2005) Dampening inflammation. Nat Immunol 6: 1179-1181.
11. Wunder A, Muller-Ladner U, Stelzer EH, Funk J, Neumann E, et al. (2003) Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 170: 4793-4801.
12. Fiehn C, Neumann E, Wunder A, Krienke S, Gay S, et al. (2004) Methotrexate (MTX) and albumin coupled with MTX (MTX-HSA) suppress synovial fibroblast invasion and cartilage degradation in vivo. Ann Rheum Dis 63: 884-886.
13. Warnecke A, Fichtner I, Sass G, Kratz F (2007) Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B. Arch Pharm (Weinheim) 340: 389-395.
14. Fiehn C, Kratz F, Sass G, Muller-Ladner U, Neumann E (2008) Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis. Ann Rheum Dis 67: 1188-1191.
15. Oettinger CW, D'Souza MJ (2012) Microencapsulated drug delivery: a new approach to pro-inflammatory cytokine inhibition. J Microencapsul 29: 455-462.
16. Gayakwad SG, Bejugam NK, Akhavein N, Uddin NA, Oettinger CE, et al. (2009) Formulation and in vitro characterization of spray-dried antisense oligonucleotide to NF-kappaB encapsulated albumin microspheres. J Microencapsul 26: 692-700.
17. Siwale RC, Oettinger CW, Pai SB, Addo R, Uddin N, et al. (2009) Formulation and characterization of catalase in albumin microspheres. J Microencapsul 26: 411-419.
18. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, et al. (1997)Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337: 141-147.
19. Akhavein N, Oettinger CW, Gayakwad SG, Addo RT, Bejugam NK, et al. (2009) Treatment of adjuvant arthritis using microencapsulated antisense NF-κB oligonucleotides. J Microencapsul 26: 223-234.
20. Das S, Banerjee R, Bellare J (2005) Aspirin loaded albumin nanoparticles by coacervation: implications in drug delivery. Trends Biomater Artif Organs 18: 203-212.
21. Paulos CM, Turk MJ, Breur GJ, Low PS (2004) Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 56: 1205-1217.
22. van der Heijden JW, Oerlemans R, Dijkmans BA, Qi H, van der Laken CJ, et al. (2009) Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum 60: 12-21.
23. Thomas TP, Goonewardena SN, Majoros IJ, Kotlyar A, Cao Z, et al. (2011) Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum 63: 2671-2680.
24. Turk MJ, Breur GJ, Widmer WR, Paulos CM, Xu LC, et al. (2002) Folatetargeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum 46: 1947-1955.
25. Rollett A, Reiter T, Nogueira P, Cardinale M, Loureiro A, et al. (2012) Folic acidfunctionalized human serum albumin nanocapsules for targeted drug delivery to chronically activated macrophages. Int J Pharm 427: 460-466.
26. Rink T, Heuser T, Fitz H, Schroth HJ, Weller E, et al. (2001) Lymphoscintigraphic sentinel node imaging and gamma probe detection in breast cancer with Tc-99m nanocolloidal albumin: results of an optimized protocol. Clin Nucl Med 26: 293-298.
27. Wang YF, Chuang MH, Chiu JS, Cham TM, Chung MI (2007) On-site preparation of technetium-99m labeled human serum albumin for clinical application. Tohoku J Exp Med 211: 379-385.
28. Breedveld FC, van Kroonenburgh MJ, Camps JA, Feitsma HI, Markusse HM, et al. (1989) Imaging of inflammatory arthritis with technetium-99m-labeled IgG. J Nucl Med 30: 2017-2021.
29. Adams BK, Al Attia HM, Khadim RA, Al Haider ZY (2001) 99Tc(m) nanocolloid scintigraphy: a reliable way to detect active joint disease in patients with peripheral joint pain. Nucl Med Commun 22: 315-318.
30. Tishler M, Lysyy O, Levy O, Volkov O, Golan H (2010) 99m Tc-albumin nanocolloid joint scintigraphy in rheumatoid arthritis patients who are in clinical remission-is remission real? Clin Exp Rheumatol 28: 360-364.
31. Liberatore M, Clemente M, Iurilli AP, Zorzin L, Marini M, et al. (1992) Scintigraphic evaluation of disease activity in rheumatoid arthritis: a comparison of technetium-99m human non-specific immunoglobulins, leucocytes and albumin nanocolloids. Eur J Nucl Med 19: 853-857.
32. Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, et al. (2006) Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 54: 1856-1866.
33. Schiff MH (2000) Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis 59: i103-i108.
34. Liu M, Huang Y, Hu L, Liu G, Hu X, et al. (2012) Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. BMC Biotechnol 12: 68.
35. Uddin MN, Siddiq A, Oettinger CW, D'Souza MJ (2011) Potentiation of proinflammatory cytokine suppression and survival by microencapsulated dexamethasone in the treatment of experimental sepsis. J Drug Target 19: 752-760.